To determine that the effect of the AVP antagonist was specific to the area postrema, baroreflex inhibitory effects on RSNA in response to intravenous phenylephrine and AVP were compared under control conditions and after administration of 100 ng of the AVP antagonist intravenously (n=3) or microinjection into the medial nucleus tractus solitarius (NTS) 750 ,gm lateral to the area postrema site and at a depth of 200-300 ,am (n=2).
Vasopressin. The brain stem was exposed as in the previous experiments, and a glass micropipette filled with AVP was inserted into the area postrema. Vasopressin was then injected into the area postrema in volumes ranging from 2 to 20 nl (2 to 20 ng), and effects on resting arterial pressure, heart rate, and RSNA were observed. Volumes of AVP were administered as single pulses or slowly injected by a series of short-duration pressure pulses. In three animals, the AVP receptor antagonist (15 ,g/kg) was administered intravenously, and microinjection of AVP into the area postrema was repeated. As a control for nonspecific pressure effects, equivalent volumes of artificial cerebrospinal fluid were injected into the area postrema.
In six rabbits, increasing doses of phenylephrine (0.5-12 1,g/kg/min) were infused intravenously for 1-minute periods, and baroreflex curves were constructed. After a recovery period, vasopressin was continuously pulsed into the area postrema by short-duration (100-500-msec) pressure (0.1-3.0 atm) pulses at a rate that produced an average sustained reduction in resting RSNA of 7±3%. After RSNA stabilized at this level, infusions of phenylephrine were repeated while the injection of AVP was continued. Baroreflex responses to phenylephrine under control conditions and during AVP microinjection were then compared. The order of infusion under control conditions or during AVP microinjection was randomized.
Data Analysis
Effects of microinjection of the AVP antagonist or of AVP into the area postrema on resting arterial pressure, heart rate, and RSNA were evaluated by paired t test. Baroreflex function relating increases in arterial pressure with phenylephrine or AVP to RSNA was analyzed with linear regression analysis. Slopes of baroreflex curves for phenylephrine and AVP under control conditions or after intravenous administration of AVP antagonist into the NTS or area postrema were compared with two-way analysis of variance. The Student-Newman-Keuls multiple range test was used to determine significance when indicated by analysis of variance. Slopes of baroreflex curves for phenylephrine under control conditions and during administration of AVP into the area postrema were compared by paired t test. A probability level of p<0.05 was considered to be statistically significant. 
Results
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Average resting mean arterial pressure and heart rate before any experimental manipulations were 83±5 mm Hg and 231 + 12 beats/min, respectively. Baroreflex curves relating increases in mean arterial pressure to inhibition of RSNA during intravenous infusions of sequentially increasing doses of phenylephrine and AVP under control conditions are presented in Figure 1 . Progressive increases in mean arterial pressure with phenylephrine resulted in a linearly related reflex decrease in RSNA, with a slope of -3.95±0.26 %RSNA/mm Hg and r=-0.97±0.01 (Table 1) . When arterial pressure was raised with systemic administration of AVP, the reflex inhibition of RSNA in response to any given increase in arterial pressure was greater than observed with phenylephrine. This is reflected in a significantly greater slope of the baroreflex relation (-8.84±0 .89 %RSNA/ mm Hg, r= -0.96+0.01) for AVP as compared with phenylephrine. Baroreflex inhibition of heart rate Table 1 ), indicating that normal baroreflex function was not altered by local injection of the AVP antagonist into the area postrema. However, baroreflex responses to intravenous AVP were now similar to those observed for phenylephrine. The slope of the baroreflex relation for intravenous AVP after local injection of AVP antagonist into the area postrema was significantly reduced compared with control conditions or after intravenous ( under control conditions and during local administration of AVP into the area postrema is illustrated in Figure 5 (n=6). During continuous administration of AVP into the area postrema at a rate that produced an average reduction in RSNA of 7+3%, baroreflex inhibition of RSNA in response to increases in arterial pressure was greater for any given pressure than observed under control conditions. Because the baseline level of RSNA was altered slightly by microinjection of AVP, the slope of the baroreflex relation was calculated both from the level of RSNA after stabilization of the response to AVP ( Figure 5 ) and from the original control value before administration of AVP. When the level of RSNA attained during local administration of AVP into the area postrema was used as the baseline value (100%) of RSNA, the slope of the mean arterial pressure-RSNA relation was significantly augmented during local application of AVP (-7 Discussion The circulating peptide hormone AVP augments the inhibitory effects of arterial baroreflexes. Baroreflex inhibition of renal or lumbar sympathetic nerve activity and heart rate is significantly greater during elevations in arterial pressure produced by infusions of AVP compared with equivalent pressure elevations caused by phenylephrine. This sympathoinhibitory action is dependent on an intact area postrema.4,11 Recent studies8 indicate that the response to lowintensity electrical or chemical (L-glutamate) stimulation of the area postrema resembles the actions of circulating AVP on baroreflex function. The effects of directly activating the area postrema include inhibition of resting RSNA as well as augmentation of the inhibitory effects of the baroreflex on RSNA. In view of these previous studies, it was postulated that AVP acts at the area postrema to augment the inhibitory effects of baroreceptors.
Previous studies have suggested that the actions of vasopressin to augment baroreflex inhibition of sympathetic nerve activity are related to sensitization of the baroreceptors12 or to an inhibition of sympathetic ganglionic transmission.3 In contrast, the findings of the present study provide strong support for a central rather than peripheral site of action of AVP. Perhaps the most pertinent result is that microinjection of the V1 receptor antagonist (100 ng in 10 nl) directly into the area postrema completely abolished the augmentation of baroreflex responses to intravenous infusions of AVP. This same amount of AVP antagonist was without effect when delivered peripherally or into the NTS. If the mechanism of action of AVP were at the ganglionic level or at the level of peripheral baroreceptors, then central administration of AVP antagonist would not be expected to completely eliminate baroreflex augmentation by circulating vasopressin. These peripheral mechanisms may be operative, but their relative contribution to augmentation of the baroreflex is minor compared with the central effect. The importance of these peripheral mechanisms may, however, become more significant in conjunction with the central action of circulating AVP.
It is important to note that microinjection of the V1 antagonist into the area postrema specifically abolished the enhancement of baroreflex inhibition of RSNA in response to AVP without altering normal baroreflex function. After injection of the antagonist into the area postrema, baroreflex effects of phenylephrine infusions were not modified, and increases in pressure during AVP infusions elicited reflex responses similar to those obtained with phenylephrine. Thus, the area postrema appears to specifically mediate the effects of AVP to modulate baroreflex function through a V1 receptor mechanism.
The importance of the area postrema in mediating the interaction of circulating AVP with baroreflex function is further supported by the fact that microinjection of AVP directly into the area postrema produced a significant inhibition of RSNA at rest and a significant augmentation of baroreflex inhibition of RSNA in response to increases in pressure with phenylephrine. The effects of injection of AVP could be eliminated by intravenous administration of the V1 antagonist. It is possible that some of the AVP that was injected into the area postrema leaked into the circulation through the dense vasculature in this region, accounting for some of the variability in response to AVP injection. Thus, some of the effects observed may have been due to an action of circulating AVP at a site other than the area postrema. For example, the median preoptic nucleus has been suggested as a site that may be involved in the effects of AVP on heart rate. 13 However, the fact that area postrema lesions, and in particular that microinjection of the AVP antagonist into the area postrema, blocks the effects of circulating AVP on baroreflex function supports the concept that the major site of action for the effects of AVP on the baroreflex is at the area postrema. These data also support previous work6'9 '1' that The effective spread of AVP or its antagonist is difficult to gauge without direct measurement. Several factors, such as available extracellular space, the number of receptors on regional neurons, and pharmacodynamics, would all affect the drug spread and response. The possibility that the observed responses are due to the spread of AVP from the area postrema into surrounding structures, particularly the NTS, is unlikely. Theoretical calculations21 predict that injectate concentrations would fall very rapidly within small distances (<300 gm) from the injection site when administered in similar volumes and concentrations as those used in this study. AVP inactivation mechanisms such as hydrolysis or active uptake by surrounding neurons or glia would further reduce the effective spread. The short latency onset of inhibition of RSNA after AVP injection is also not consistent with the idea of drug spread into the surrounding tissue. These observations strongly support the area postrema as the site of action of AVP, rather than adjacent structures.
The actions of AVP need not be confined to neurons intrinsic to the area postrema. Golgi studies of this region in cats indicate that some NTS neurons, particularly those with somas bordering the area postrema, send dendritic arborizations into the area postrema.2223 Thus, it is possible that AVP could activate these neuronal processes. Lesions of the area postrema, or microinjections of drugs, could not effectively discriminate between activation of dendrites of NTS neurons and neurons residing entirely within the area postrema. However, the rather limited extent of arborization of these dendrites and their confinement to the deep portions of the area postrema24 diminishes their possible importance in mediating AVP responses. A more likely possibility involves catecholaminergic neurons intrinsic to the area postrema. These cells reside in close proximity to blood vessels within the area postrema and form numerous axodendritic synapses within the adjacent dorsolateral and medial NTS.25 Recent work from this laboratory26 indicates that intracisternal 6-hydroxydopamine treatment eliminates the augmentation of the baroreflex by intravenous AVP. Depletion of catecholamine terminals in the adjacent NTS appears to be related to the effects of 6-hydroxydopamine.
The lack of major effect of the AVP antagonist on resting RSNA, blood pressure, or heart rate suggests several possibilities concerning AVP's actions on the neurons producing the reflex inhibitory responses. AVP may excite neurons with somatodendritic membranes in the vicinity of the injection pipette, but these neurons may not fire spontaneously or may discharge with a low spontaneous rate in our experimental preparation. Therefore, AVP receptor blockade would have no substantial effect. The lack of effect of AVP antagonist on baroreflex function also suggests that endogenous levels of AVP in anesthetized rabbits may not be sufficiently high to influence neurons in the area postrema or that these neurons have adapted to the given level of circulating AVP.
In summary, microinjection of the specific V1 AVP receptor antagonist into the area postrema eliminated the ability of intravenous AVP to augment arterial baroreflex inhibition of RSNA, without altering normal baroreflex responses to phenylephrine. In addition, microinjection of AVP into the area postrema inhibited resting RSNA and augmented the inhibitory effects of arterial baroreflexes. These data suggest that the area postrema mediates the modulation of baroreflex function by circulating AVP via a V1 receptor mechanism.
